(AGENPARL) - Roma, 5 Dicembre 2024 - (AGENPARL) – gio 05 dicembre 2024 Data from the trial is expected to be shared in 2025
Lund, Sweden, 5 December 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA)
today announced it has completed the enrolment of patients in the GOOD-IDES-02
trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti
-GBM) disease. Anti-GBM is a rare, severe autoimmune condition affecting around
1.6 people per million annually.[1] Imlifidase has been granted orphan drug
designation for the treatment of anti-GBM disease by both the U.S. FDA and the
European Medicines Agency (EMA). Enrolment completion was originally planned for
2025.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “We are very pleased
with the fast enrolment of all 50 patients in the GOOD-IDES-02 trial. The
completion of patient enrolment in this pivotal Phase 3 trial is an important
milestone in our efforts to investigate the potential role for imlifidase to
address the high unmet need in anti-GBM. The majority of patients with anti-GBM
today lose kidney function and two-thirds experience kidney failure requiring
long-term dialysis. We look forward to sharing further updates on the outcome of
the study and potential path forward in 2025.”
Anti-GBM is Hansa Biopharma’s most advanced program in the autoimmune space.
GOOD-IDES-02 is an open label, multi-center Phase 3 trial involving over 40
centers across the US, UK, and EU. A total of 50 patients have been enrolled in
the trial. In the trial, 25 patients were randomized to receive imlifidase in
combination with standard of care (SoC), consisting of a combination of
immunosuppressives, glucocorticoids, and plasma exchange, and 25 patients
received only SoC. The primary objective of the study is to assess the superior
effect on kidney function of imlifidase in combination with SoC versus SoC alone
in the treatment of patients affected by severe anti-GBM disease. The
performance of the treatment is assessed at 6 months through the evaluation of
renal function as measured by estimated glomerular filtration rate (eGFR) and
need of dialysis. In addition, the safety profile and efficacy on pulmonary
symptoms and health related quality of life aspects are evaluated.
More information about the trial is available at ClinicalTrials.gov under
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About anti-GBM disease
Anti-glomerular basement membrane (anti-GBM) disease, also known as Goodpasture
disease, is a rare, severe autoimmune condition affecting around 1.6 people per
million annually[1] with majority of patients losing their kidney function.[2,3]
In anti-GBM disease, the immune system mistakenly develops antibodies against an
antigen intrinsic to the glomerular basement membrane, resulting in an acute
immune attack of the kidneys and, in around half of the patients, also the
lungs. Approximately two thirds of anti-GBM patients will experience kidney
failure and require long-term dialysis while awaiting potential kidney
transplantation.[4] Some patients may also experience bleeding from the lungs.
In one out of six patients, anti-GBM disease can become fatal during the acute
phase.
Imlifidase has been granted orphan drug designation for the treatment of anti
-GBM disease by both the U.S. FDA and the European Medicinal Agency (EMA).
About imlifidase
Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets IgG and inhibits IgG-mediated immune
response.[5] It has a rapid onset of action, cleaving IgG-antibodies and
inhibiting their activity within hours after administration. Imlifidase has
conditional marketing approval in Europe and is marketed under the trade name
IDEFIRIX[®] for the desensitization treatment of highly sensitized adult kidney
transplant patients with a positive crossmatch against an available deceased
donor.[5]
About imlifidase and autoimmune diseases
Autoimmune diseases form a group of serious diseases caused by the immune system
attacking the body. In many autoimmune diseases the immune system mistakenly
recognizes the body’s own proteins, as foreign and mounts an immune response,
creating antibodies to attack the body’s own cells and tissues.[6-8] Pathogenic
IgG can contribute to a broad spectrum of autoimmune diseases.
Hansa Biopharma is exploring how imlifidase and HNSA-5487 may be able to prevent
or slow the progression of these diseases and their debilitating, life
-threatening symptoms. Imlifidase is currently being studied in the following
autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and
Guillain-Barré Syndrome (GBS).
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
References
1. Canney M, et al. Spatial and Temporal Clustering of Anti-Glomerular Basement
Membrane Disease. Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1392-1399. doi:
2. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am
3. Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc
4. Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture’s
disease (anti-GBM). J Autoimmun. 2014 Feb-Mar;48-49:108-12. doi:
5. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
6. Angum F, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative
Review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094.
7. Wang L, et al. Human autoimmune diseases: a comprehensive update. J Intern
Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395.
8. Ma H, Murphy C, Loscher CE and O’Kennedy R (2022) Autoantibodies – enemies,
and/or potential allies? Front. Immunol. 13:953726. doi:
10.3389/fimmu.2022.953726
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2HWjpLv1XyYCkP1Wqcd1azhoz1b9hvK73ZKFH1bpBdsz5K7zk6YkSJkbhKr5YBoVebfehNjRsj3bvxLt9ND575gdztpjeDLv5chN5FNsMzSEUL.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2HWjpLv1XyYCkP1Wqcd1azhoz1b9hvK73ZKFH1bpBdsz5K7zk6YkSJkbhKr5YBoVebfehNjRsj3bvxLt9ND575gdztpjeDLv5chN5FNsMzSEUL.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- La Cina rafforza la sua influenza in Asia centrale: accordo strategico sul gas in Kazakistan e nuove intese economiche nella regione
- Rifondazione Comunista: ddl anti Palestina liberticida, campo largo si impegni a abrogarlo
- COMUNICATO STAMPA CONSIGLIO DEI MINISTRI N. 198 18/11/2026 PALAZZO CHIGI
- Riforma forense, Ostellari (Lega): impegno mantenuto, più garanzie per avvocati e cittadini
- FEMMINICIDIO: BILOTTI (M5S), A SALERNO 3 DONNE UCCISE IN POCHE ORE. NON SI SPOSTI FULCRO DA VIOLENZA
- BOSCAINI (FI) AL GOVERNO: “SIANO VERIFICATE LE COPERTURE FINANZIARIE DEL PROGETTO DI POTENZIAMENTO, CHE VA REALIZZATO ENTRO 6 ANNI, PRIMA DELLA GALLERIA DEL BRENNERO”
- MANOVRA: DOMANI CONFERENZA STAMPA FDI ALLA CAMERA SUGLI INTERVENTI PER L’AGRICOLTURA
- DL CORTEI. ZUCCONI (FDI): PLAUSO A EMENDAMENTO STOP SOCIAL UNDER 13. UNA BATTAGLIA DI CIVILTÀ
- DDL ANTISEMITISMO: ORSINI (FI), “IL DIRITTO DI ESSERE ANTISEMITI NON FA PARTE DELLA LIBERT?
- DDL ANTISEMITISMO: ORSINI (FI), “SCHLEIN INCOERENTE SULLA DEFINIZIONE IHRA